Health
Egypt's drug authority flags unregistered intravenous NAD+ promoted by an aesthetic clinic
Coverage
2 reports · over 1 hour
Egypt's Drug Authority said an Instagram advertisement for an unregistered intravenous NAD+ drip carried misleading marketing claims, and warned of infection and allergic risks.
- The authority recorded the advertisement in violation report AVU-38-26, saying it was posted on February 12, 2026 by the Instagram account "opalaestheticseg".
- The ad promoted an "NAD+ IV Drip" under the line "Support your cells from within," the authority said.
- The authority said contaminated or unsafely prepared solutions could cause serious infection or toxic reactions, and warned of vein inflammation and allergic reactions.
- The authority advised pregnant and breastfeeding women and patients with liver, kidney, heart or active cancer conditions to obtain medical assessment before use.

